Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration

American Journal of Health-System Pharmacy

Volumn 74, Issue 1, 2017, Pages e47-e54

  Thabit, Abrar K ^a,b   Hamada, Yukihiro ^a,c   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antibiotic; Ceftolozane tazobactam; Compatibility; Infection; Intravenous; PH

Indexed keywords

AMIKACIN; AMIODARONE; AMPHOTERICIN B; ANIDULAFUNGIN; AZITHROMYCIN; AZTREONAM; BUMETANIDE; CALCIUM CHLORIDE; CASPOFUNGIN; CEFAZOLIN; CEFEPIME; CEFTAROLINE FOSAMIL; CEFTAZIDIME; CEFTOLOZANE PLUS TAZOBACTAM; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CYCLOSPORIN; DEXAMETHASONE SODIUM PHOSPHATE; DEXMEDETOMIDINE; DIGOXIN; GLUCONATE CALCIUM; HUMAN ALBUMIN; METRONIDAZOLE; NICARDIPINE; PHENYTOIN; PROPOFOL; SULTAMICILLIN; UNINDEXED DRUG; ANTIINFECTIVE AGENT; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; EXCIPIENT; GLUCOSE; PENICILLANIC ACID; SODIUM CHLORIDE;

ARTICLE; COLOR; CONTROLLED STUDY; DRUG INCOMPATIBILITY; DRUG SOLUTION; PH; PRECIPITATION; PRIORITY JOURNAL; SIMULATION; TURBIDITY; ANALOGS AND DERIVATIVES; CHEMISTRY; DEVICES; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; PHOTOMETRY; PROCEDURES; SOLUBILITY; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CHEMISTRY, PHARMACEUTICAL; DRUG INCOMPATIBILITY; EXCIPIENTS; GLUCOSE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; NEPHELOMETRY AND TURBIDIMETRY; PENICILLANIC ACID; SODIUM CHLORIDE; SOLUBILITY; URINARY TRACT INFECTIONS;

EID: 85007228604     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp150762     Document Type: Article

References (10)

1. Zerbaxa (ceftolozane-tazobactam) package insert. Lexington, MA: Cubist Pharmaceuticals; 2014.
2. Allen LV Jr, Levinson RS, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm. 1977; 34:939-43.
3. Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm. 1993; 50:2359-63.
4. Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm. 1992; 49:1716-9.
5. Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection, part 2. Am J Hosp Pharm. 1993; 50:300-4.
6. Housman ST, Tessier PR, Nicolau DP, Kuti JL. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm. 2011; 68:2265-70.
7. Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected medications during simulated Y-site administration. Am J Health-Syst Pharm. 1997; 54:1287-9.
8. Newton DW. Drug incompatibility chemistry. Am J Health-Syst Pharm. 2009; 66:348-57.
9. Maxipime (cefepime hydrochloride) package insert. Princeton, NJ: Bristol-Myers Squibb; 2009.
10. Rocephin (ceftriaxone sodium) package insert. South San Francisco, CA: Genetech USA; 2015.